Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
- PMID: 38347836
- PMCID: PMC10859502
- DOI: 10.3389/fonc.2024.1309687
Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
Abstract
Transducin beta-like 1X-related protein 1 (TBL1XR1) was discovered two decades ago and was implicated as part of the nuclear transcription corepressor complex. Over the past 20 years, the emerging oncogenic function of TBL1XR1 in cancer development has been discovered. Recent studies have highlighted that the genetic aberrations of TBL1XR1 in cancers, especially in hematologic tumors, are closely associated with tumorigenesis. In solid tumors, TBL1XR1 is proposed to be a promising prognostic biomarker due to the correlation between abnormal expression and clinicopathological parameters. Post-transcriptional and post-translational modification are responsible for the expression and function of TBL1XR1 in cancer. TBL1XR1 exerts its functional role in various processes that involves cell cycle and apoptosis, cell proliferation, resistance to chemotherapy and radiotherapy, cell migration and invasion, stemness and angiogenesis. Multitude of cancer-related signaling cascades like Wnt-β-catenin, PI3K/AKT, ERK, VEGF, NF-κB, STAT3 and gonadal hormone signaling pathways are tightly modulated by TBL1XR1. This review provided a comprehensive overview of TBL1XR1 in tumorigenesis, shedding new light on TBL1XR1 as a promising diagnostic biomarker and druggable target in cancer.
Keywords: TBL1XR1; oncogene; signaling pathways; therapeutic target; upstream regulators.
Copyright © 2024 Du, Li, Guo, Chen, Zhao, Han and Bian.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation of NF-κB pathway.Mol Cancer. 2014 Aug 22;13:195. doi: 10.1186/1476-4598-13-195. Mol Cancer. 2014. PMID: 25145705 Free PMC article.
-
TBL1XR1 in physiological and pathological states.Am J Clin Exp Urol. 2015 Apr 25;3(1):13-23. eCollection 2015. Am J Clin Exp Urol. 2015. PMID: 26069883 Free PMC article. Review.
-
TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma.World J Gastroenterol. 2020 Jul 7;26(25):3586-3602. doi: 10.3748/wjg.v26.i25.3586. World J Gastroenterol. 2020. PMID: 32742128 Free PMC article.
-
Transducin (β)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway.Oncogene. 2017 Mar 30;36(13):1873-1886. doi: 10.1038/onc.2016.352. Epub 2016 Oct 3. Oncogene. 2017. PMID: 27694893 Free PMC article.
-
TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.Exp Hematol. 2022 Dec;116:18-25. doi: 10.1016/j.exphem.2022.09.006. Epub 2022 Oct 4. Exp Hematol. 2022. PMID: 36206873 Free PMC article. Review.
Cited by
-
Proteomic characterization of MET-amplified esophageal adenocarcinomas reveals enrichment of alternative splicing- and androgen signaling-related proteins.Cell Mol Life Sci. 2025 Mar 13;82(1):112. doi: 10.1007/s00018-025-05635-7. Cell Mol Life Sci. 2025. PMID: 40074836 Free PMC article.
-
The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer.Cancers (Basel). 2025 Jan 19;17(2):308. doi: 10.3390/cancers17020308. Cancers (Basel). 2025. PMID: 39858090 Free PMC article.
-
The alternative polyadenylation regulator CFIm25 promotes macrophage differentiation and activates the NF-κB pathway.Cell Commun Signal. 2025 Feb 28;23(1):115. doi: 10.1186/s12964-025-02114-1. Cell Commun Signal. 2025. PMID: 40022203 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous